Image

Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction

Impact of Cardio-Selective Beta-Blockers on Infarct Size After Acute Myocardial Infarction

Recruiting
18-80 years
All
Phase N/A

Powered by AI

Overview

Introduction: The effect of intravenous beta-blockers on the extent of the necrotic area, after primary percutaneous transluminal coronary angioplasty (PTCA), for acute myocardial infarction is not well established.

Purpose: The present study aims to investigate, whether the early intravenous administration of landiolol, a highly cardioselective b-blocker, reduces the extent of the necrotic area after ST-elevation myocardial infarction (STEMI).

Methods: This prospective observational cohort study will enroll patients presenting with STEMI, who undergo primary PCI and receive either intravenous landiolol or standard oral β-blocker therapy, in accordance with current European Society of Cardiology (ESC) guidelines. Eligibility will be determined by predefined inclusion and exclusion criteria. Treatment selection will be based solely on the clinical judgment of the attending cardiologist, without randomization.

Results: Final infarct size will be quantified by cardiac magnetic resonance imaging (CMR) performed at least three months after the STEMI to minimize edema-related overestimation. Myocardial function will be assessed during hospitalization using transthoracic echocardiography, including measurement of global longitudinal strain (GLS). Additional data will include serial high-sensitivity troponin and creatine phosphokinase (CPK) measurements, 24-hour continuous electrocardiographic monitoring for arrhythmia burden, and predefined safety outcomes collected throughout hospitalization.

Eligibility

Inclusion Criteria:

  • Age between 18 and 80 years
  • Patients with electrocardiogram showing ST-segment elevation ≥2 mm in 2 or more contiguous leads for more than 30 minutes
  • Estimated time from symptom onset to reperfusion ≤12 hours
  • Patients scheduled to undergo primary angioplasty
  • Patients who have signed a consent form

Exclusion Criteria:

  • Patients receiving chronic medication with beta-adrenergic blockers
  • Patients with a previous myocardial infarction
  • Persistent systolic blood pressure \<90 mmHg
  • Persistent heart rate \<55 beats per minute
  • Patients with Killip class III (acute pulmonary edema) or IV (cardiogenic shock) on initial examination
  • 12-lead electrocardiogram with PR interval \>200 milliseconds
  • 12-lead electrocardiogram showing second- or third-degree atrioventricular block
  • Bronchospasm requiring bronchodilator treatment
  • Possible pregnancy or postpartum period
  • Inability or refusal to sign the consent form

Study details
    STEMI

NCT07293832

Aristotle University Of Thessaloniki

31 January 2026

Step 1 Get in touch with the nearest study center
We have submitted the contact information you provided to the research team at {{SITE_NAME}}. A copy of the message has been sent to your email for your records.
Would you like to be notified about other trials? Sign up for Patient Notification Services.
Sign up

Send a message

Enter your contact details to connect with study team

Investigator Avatar

Primary Contact

  Other languages supported:

First name*
Last name*
Email*
Phone number*
Other language

FAQs

Learn more about clinical trials

What is a clinical trial?

A clinical trial is a study designed to test specific interventions or treatments' effectiveness and safety, paving the way for new, innovative healthcare solutions.

Why should I take part in a clinical trial?

Participating in a clinical trial provides early access to potentially effective treatments and directly contributes to the healthcare advancements that benefit us all.

How long does a clinical trial take place?

The duration of clinical trials varies. Some trials last weeks, some years, depending on the phase and intention of the trial.

Do I get compensated for taking part in clinical trials?

Compensation varies per trial. Some offer payment or reimbursement for time and travel, while others may not.

How safe are clinical trials?

Clinical trials follow strict ethical guidelines and protocols to safeguard participants' health. They are closely monitored and safety reviewed regularly.
Add a private note
  • abc Select a piece of text.
  • Add notes visible only to you.
  • Send it to people through a passcode protected link.